PortalsOS

We do know now that if we catch the cancer early enough, even if you fail chemo, you fail radiation, brain tumors, we now have patients with brain tumors who have failed everything, come to see us. We're getting almost a complete response.

The FDA keeps telling you, no, no, no, not unless you do these trials. So I don't know in our lifetime, will we get... So are we going to avoid ovarian cancer? Are we going to avoid triple negative breast cancer? Are we going to avoid pancreatic cancer?

I'm getting calls for young ladies with triple negative breast cancer in their 30s. I'm getting calls for glioblastoma, which we have failed.

The drug Cerolimus, originally for organ transplant rejection, has kept Dr. Fagenbaum in remission for over 11 years.

We've done this with healthy volunteers already. More importantly, the NCI then designated us to treat patients without cancer, i.e. patients with what we call Lynch syndrome.

The FDA refused to file our data for bladder cancer treatment, even though we have patients alive and cancer-free for 10 years. It's mystifying!

The story of Michael, a patient with metastatic angiosarcoma who benefited from a repurposed drug, illustrates the life-changing potential of drug repurposing.

If you go to csfifm.org or .com, you will see the trials that I'm now open as randomized trials. So we're now taking patients with lung cancer who failed in.